Compare · ORKA vs QCLS
ORKA vs QCLS
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Q/C Technologies Inc. (QCLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QCLS operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.53B, about 204.1x QCLS ($27.1M).
- Over the past year, ORKA is up 588.6% and QCLS is down 72.6% - ORKA leads by 661.3 points.
- ORKA has been more active in the news (4 items in the past 4 weeks vs 2 for QCLS).
- ORKA has more recent analyst coverage (11 ratings vs 0 for QCLS).
PerformanceORKA+588.65%QCLS-72.63%
2025-07-21+0.00%2026-07-21
- Company
- Oruka Therapeutics Inc.
- Q/C Technologies Inc.
- Price
- $94.62+3.21%
- $3.50+1.45%
- Market cap
- $5.53B
- $27.1M
- 1M return
- +30.65%
- -12.94%
- 1Y return
- +588.65%
- -72.63%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 4
- 2
- Recent ratings
- 11
- 0
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)
Latest QCLS
- Q/C Technologies Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events
- Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Director Voss Chelsea Sierra bought $5,522 worth of shares (1,753 units at $3.15) (SEC Form 4)
- Amendment: SEC Form 10-K/A filed by Q/C Technologies Inc.
- SEC Form 4 filed by White Billy Joe
- SEC Form 4 filed by Friscia Stephen
- SEC Form 4 filed by Voss Chelsea Sierra
- SEC Form 4 filed by Bernstein Bruce
- SEC Form 4 filed by Glass Mitchell